Neeraj Narula
Population Health Research Institute
Internal medicineSurgeryOdds ratioRetrospective cohort studyIntensive care medicineProspective cohort studyAdverse effectVedolizumabInfliximabInflammatory bowel diseaseColonoscopyUstekinumabDiseaseCrohn's diseaseAdalimumabUlcerative colitisIn patientConfidence intervalPost-hoc analysisMedicineGastroenterologyMeta-analysis
140Publications
23H-index
1,880Citations
Publications 146
Newest
#1C Frias GomesH-Index: 1
#2Neeraj NarulaH-Index: 23
Last. J TorresH-Index: 3
view all 6 authors...
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Brad MillsonH-Index: 3
Last. John Marshall (McMaster University)H-Index: 89
view all 10 authors...
Background: Adalimumab is an antitumour necrosis factor (TNFα) biologic therapy indicated for the treatment of Crohn's disease (CD). Patients receiving adalimumab in Canada are eligible to enroll in the AbbVie Care™ patient support program (AC-PSP), which provides personalized services, including care coach calls (CCCs). The objective of this study was to compare the likelihood of achieving clinical remission in a cohort of CD patients treated with adalimumab who did and did not receive CCCs. Me...
1 CitationsSource
#1Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
#2Brigid S. Boland (UCSD: University of California, San Diego)H-Index: 21
Last. Charlie Cao (Takeda Pharmaceutical Company)H-Index: 5
view all 36 authors...
Background & Aims As more treatment options for inflammatory bowel diseases become available, it is important to identify patients most likely to respond to different therapies. We created and validated a scoring system to identify patients with Crohn’s disease (CD) who respond to vedolizumab. Methods We collected data from the GEMINI 2 phase 3 trial of patients with active CD treated with vedolizumab for 26 weeks (n = 814) and performed logistic regression analysis to identify factors associate...
47 CitationsSource
#1Neeraj Narula (McMaster University)H-Index: 23
#2Sameer Masood (Harvard University)H-Index: 1
Last. Arianne Buchan (Ottawa Hospital)H-Index: 1
view all 6 authors...
Background. The majority of children who undergo gastrointestinal (GI) endoscopy require anesthesia or procedural sedation for comfort, cooperation, and procedure efficiency. The safety profile of propofol is not well established in children but has been studied in the literature. Objective. The aim of this study is to evaluate and compare the safety of propofol-only sedation for GI endoscopy procedures to other anesthetic regimes in the pediatric population. Methods. A search was conducted in t...
10 CitationsSource
#1Reena Khanna (UWO: University of Western Ontario)H-Index: 29
#2Neeraj Narula (McMaster University)H-Index: 23
Last. Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
view all 3 authors...
: Clinical trials require valid outcome measures to assess the therapeutic benefit of investigational agents. Recently, regulatory authorities have mandated the use of patient-reported outcomes in combination with an objective measure of disease activity as primary outcome measures in inflammatory bowel disease trials. Endoscopy has commonly fulfilled the latter role; however, due to the costs and complexity of these assessments, interest has emerged in the use of noninvasive biomarkers. The rol...
5 CitationsSource
#1Neeraj Narula (McMaster University)H-Index: 23
#2Farhad Peerani (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
Last. Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
view all 37 authors...
We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, and to identify predictors of response to treatment. Retrospective review (May 2014–December 2016) of VICTORY Consortium data. Adults with follow-up after starting VDZ for clinically active UC were included. Primary effectiveness outcomes were cumulative rates of clinical remission (resolution of all UC-related symptoms) and endoscopic remission (Mayo endoscopic sub-score 0). Key secondary effectiveness outc...
70 CitationsSource
#1Priya Sehgal (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
#2Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 164
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 4 authors...
Mesalazine is the most commonly prescribed medication for mild to moderate ulcerative colitis. It is generally well tolerated with some reported side effects.To summarise adverse drug events to mesalazine and recommend techniques for management. Furthermore, to determine if there is a dose-dependent relationship between high (>2.4 g/day) vs low dosing (≤2.4 g/day) and occurrence of adverse drug events.A literature search for relevant studies from inception to 1 December 2017 of the MEDLINE datab...
27 CitationsSource
#1Shishira Bharadwaj (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 12
#2Neeraj Narula (McMaster University)H-Index: 23
Last. Mohammad Yaghoobi (McMaster University)H-Index: 22
view all 4 authors...
: Crohn's disease (CD) and ulcerative colitis (UC) constitute the two most common phenotypes of inflammatory bowel disease (IBD). Ileocolonoscopy with biopsy has been considered the gold standard for the diagnosis of IBD. Differential diagnosis of CD and UC is important, as their medical and surgical treatment modalities and prognoses can be different. However, approximately 15% of patients with IBD are misdiagnosed as IBD unclassified due to the lack of diagnostic certainty of CD or UC. Recentl...
13 CitationsSource
#1Derek H. LittleH-Index: 2
#2Neeraj NarulaH-Index: 23
Last. Joanna C. DionneH-Index: 9
view all 3 authors...
Source
#1Cindy C Y Law (McMaster University)H-Index: 2
#2Alisha Narula (McMaster University)H-Index: 2
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 6 authors...
Background and Aims: The impact of vedolizumab, a gut-selective monoclonal antibody, on postoperative outcomes is unclear. This study aimed to assess the impact of preoperative vedolizumab treatment on the rate of postoperative complications in patients with inflammatory bowel disease [IBD] undergoing abdominal surgery. Methods: A systematic search of multiple electronic databases from inception until May 2017 identified studies reporting rates of postoperative complications in vedolizumab-treat...
45 CitationsSource